Certain Antibody Drug Conjugates and Components Thereof and Products Containing the Same; Notice of a Commission Determination Not To Review an Initial Determination Terminating the Investigation; Termination of Investigation

Brief takeaway: An ITC Section 337 investigation into certain antibody drug conjugates has been terminated in full, so its potential import restrictions are no longer being pursued.

What changed: According to the notice, the Commission determined not to review the administrative law judge's initial determination (Order No. 17) that terminated the investigation in its entirety. The notice states the termination was based on withdrawal of the complaint, which ends the investigation.

Who's affected: The notice names certain antibody drug conjugates and components thereof, and products containing the same. No specific HTS chapters, codes, or countries of origin are stated in the notice. Importers dealing in these types of biopharmaceutical products may find this development relevant.

What to review:
- Review whether your products fall within the antibody drug conjugates and components described in the investigation title.
- Confirm with your broker or trade counsel whether any prior exclusion order, cease-and-desist order, or entry hold tied to this investigation is now lifted.
- Check the underlying ITC investigation docket for the full initial determination and any related orders, since the notice itself provides limited detail.

This is general information, not legal advice and not a compliance determination — confirm specifics with a licensed customs broker or trade counsel.